Clinical Trial Search

Primary: Percent Changes From Baseline in Total Lesion Counts — 58.3; 65.9; 25.5 percent change

Primary: Disease-free Survival (DFS) Rate at 2 Years in TOP2A-amplified and in TOP2A-nonamplified HER2+ ESBC Patients Treated With TC+H. — 0.978; 0.979 probability of…

Primary: Global Distribution of C11 PiB in the Brain — 2.50; 1.47; 1.23 standard uptake value ratio — p=<0.001

Primary: Progression Free Survival (PFS) — 9.5 months

Primary: Number of Participants With Objective Response — 3; 0; 4; 10 Participants

Primary: Tumor Response Rate (RR) — 8; 6; 12; 1 participants

Primary: Yale Brown Obsessive Compulsive Scale (YBOCS) Modified for PSP (NE-YBOCS) — 18.8; 17.6; 16.1; 17.3 units on a scale

Primary: Percentage of Participants Who Achieved American College of Rheumatology 20 (ACR20) Responses at Day 169 — 65.6; 62.0 percentage of participants — p=0.666

Primary: Maximum Tolerated Dose (MTD) — 50 mg/m^2

Primary: Mean Neuropathy Severity Score (FACT-GOG-Ntx Total Score Assessment) — 20.8; 16.7; 9.9; 13.2 units on a scale

Primary: Minimum Inhibitory Concentration (MIC) of KAE609

Primary: Maximum Tolerated Dose (MTD) of IV AMD3100 + G-CSF in Mobilization of Peripheral Blood Stem Cell in Patients With Lymphoma (Phase I Only) — 400 micrograms/kilograms

Primary: Number of Participants With Serum Samples Obtained on Day 8 for Assessment of Seropositivity for Both Anti-NoV GI.1 VLP and GII.4 VLP Antibodies — 48 participants

Primary: Percent Change in Biomarker (GLI2 Protein) Levels — 75 percentage decrease

Primary: Mean Change From Baseline in Body Weight at Week 12 — -0.51; -0.92 Kilogram — p=0.187